$ADTX

Aditxt (ADTX) Stock Sinks 20% After-Hours: Here’s What’s Going On - Aditxt (NASDAQ:ADTX)

Aditxt Inc. (NASDAQ:ADTX) shares fell about 20% in after-hours after Nasdaq’s Hearings Panel denied the company’s request to keep its listing, according to an 8-K filing. Nasdaq said trading will be suspended at the open on June 25. Nasdaq cited prior noncompliance, including bid price below $1 and stockholders’ equity of negative $35.17 million.

Original reporting
Published Jun 25, 2026, 6:45 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 25, 2026, 7:32 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Aditxt (ADTX) Stock Sinks 20% After-Hours: Here’s What’s Going On - Aditxt (NASDAQ:ADTX) — source image
Decision brief

The 30-second read

$ADTXBearishHigh
01

Why it matters

The Hearings Panel denial removes the temporary protection from delisting and sets a concrete suspension date, increasing near-term downside and reducing liquidity for holders and traders.

02

Market read

A concrete Nasdaq listing denial with an imminent trading suspension is a time-sensitive catalyst for ADTX positioning and risk management.

03

What to watch

The article doesn’t cover whether ADTX has a credible path to regain compliance or what venue (if any) trading may migrate to after suspension, which can materially change post-suspension dynamics.

Relevance 9/10Novelty 8/10Timing: ahead of the June 25 open when Nasdaq will suspend ADTX trading

Background

Nasdaq previously flagged non-compliance after ADTX traded below $1 for 30 consecutive business days and failed the $2.5M minimum stockholders’ equity requirement; multiple reverse splits exceeded a 250-to-1 cumulative ratio.

Company-level read

Ticker impact

$ADTXBearishHigh confidence
Context

Nasdaq Hearings Panel denied Aditxt’s request to maintain listing, and trading will be suspended at the open June 25.

Expected impact

High likelihood of continued heavy selling/illiquidity into the June 25 suspension; post-suspension pricing may become erratic or move to alternative venues.

Evidence & confidence

The article cites an 8-K and specifies the suspension timing (open of trading June 25) following denial of the listing appeal.

Market effects

Microcap listing-compliance risk remains elevated; could pressure sentiment toward other Nasdaq-listed small caps with sub-$1 bid and equity shortfalls.

Primarily US microcap liquidity and Nasdaq listing ecosystem impact.

Limited; mostly affects US trading venues and counterparties for this issuer.

Counterpoint

ADTX could still pursue a review with Nasdaq’s Listing and Hearing Review Council, potentially delaying final outcomes and creating short-term trading volatility.

Key entities

  • Aditxt Inc.

    Nasdaq-listed issuer whose listing appeal was denied and whose trading will be suspended June 25.

  • Nasdaq Hearings Panel

    Denied Aditxt’s request to maintain its listing.

  • Nasdaq Listing and Hearing Review Council

    Review body Aditxt may request within 15 days.

Related articles

$LLYMedAI 9/10

Roche and Eli Lilly receive FDA clearance for Alzheimer’s test

Roche and Eli Lilly (LLY) received FDA clearance for their Alzheimer’s blood test, Elecsys pTau217, for adults 55+ with cognitive decline. The test, already approved in Europe, can be run on Roche’s U.S. analyzers. Labcorp (LH) and Quest Diagnostics (DGX) will offer it. The test aims to replace expensive, invasive methods like PET scans. Roche did not disclose pricing. The FDA clearance comes amid demand for simpler Alzheimer’s diagnostics.

$COINMed

The Clarity Act Is on Hold, but the SEC Is Picking Up the Slack. Here's the Latest Outlook on Crypto Regulation.

The SEC proposed a digital-asset rule on Aug. 18, while President Trump met with crypto executives from Coinbase, Ripple (XRP), and Robinhood. The Clarity Act's passage is uncertain after Congress adjourned without voting. The SEC and CFTC have classified 18 crypto assets, including Bitcoin (BTC), Ethereum (ETH), XRP, and Solana (SOL), as commodities. New rules aim to exempt small token sales from registration, but regulatory changes remain uncertain.

$VNDAMedAI 8/10

Vanda Pharmaceuticals Granted Orphan Designation for Imsidolimab for the Treatment of Generalized Pustular Psoriasis by the European Commission

Vanda Pharmaceuticals (VNDA) received Orphan Designation from the European Commission for imsidolimab, a treatment for Generalized Pustular Psoriasis (GPP). The drug also has similar designations in the US and Japan. The FDA is reviewing the Biologics License Application with a target action date of December 12, 2026.